You searched for Gout - Page 26 of 96

Abstract Number: 2834 • 2019 ACR/ARP Annual Meeting
Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study
Michael Fralick¹, Sarah Chen ², Elisabetta Patorno ³ and Seoyoung C. Kim ⁴, ¹Mount Sinai Hospital, University of Toronto, Toronto, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Harvard University, Boston, ⁴Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Hyperuricemia is common in patients with type 2 diabetes mellitus and is associated with an increased risk of gout. Sodium-glucose cotransporter 2 (SGLT2) inhibitors,…
Abstract Number: 2835 • 2019 ACR/ARP Annual Meeting
A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout
Niamh Fanning¹, Ruth Topless ², Christopher Frampton ¹, Murray Cadzow ², Mary Wallace ³, Nicola Dalbeth ⁴, Tony Merriman ⁵ and Lisa Stamp ⁶, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²University of Otago, Otago, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵University of Otago, Birmingham, AL, ⁶University of Otago, Christchurch, Christchurch, Canterbury, New Zealand
Background/Purpose: Current understanding of why the urate lowering effect of allopurinol varies among individuals with gout is limited. The rs2231142 (Q141K) variant of ABCG2 is…
Abstract Number: 2836 • 2019 ACR/ARP Annual Meeting
Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank
Vicky Tai¹, Ravi Narang ¹, Greg Gamble ¹, Lisa Stamp ², Tony Merriman ³ and Nicola Dalbeth ¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ³University of Otago, Birmingham, AL
Background/Purpose: Both serum urate-associated genetic variants and body mass index (BMI) are associated with gout risk. The aim of this study was to systematically examine…
Abstract Number: 2838 • 2019 ACR/ARP Annual Meeting
The First Phase 2a Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout
Tim Jansen¹, Viola Kluck ², Matthijs Janssen ³, Antoaneta Comarniceanu ³, Monique Efdé ³, Curtis Scribner ⁴, Damaris Skouras ⁵, Charles Dinarello ⁶ and Leo Joosten ⁷, ¹Viecuri MC, Venlo, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³VieCuri Medical Center, Venlo, Netherlands, ⁴Olatec Therapeutics LLC, New York, ⁵Olatec Therapeutics LLC, New York, NY, ⁶University of Colorado Denver, Aurora, CO, ⁷Department of Internal Medicine and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Acute gout is a severe debilitating type of arthritis that is treated in the acute phase with potent anti-inflammatory drugs. To date, prednisolone, colchicine…
Abstract Number: 2839 • 2019 ACR/ARP Annual Meeting
Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts
Nicholas Sumpter¹, Tony Merriman ², Richard Reynolds ³, Abhishek Abhishek ⁴, Mariano Andrés ⁵, Nicola Dalbeth ⁶, Michael Doherty ⁴, Lennart Jacobsson ⁷, Matthijs Janssen ⁸, Tim Jansen ⁹, Leo Joosten ¹⁰, Meliha Kapetanovic ¹¹, Frédéric Lioté ¹², Hirotaka Matsuo ¹³, Geraldine McCarthy ¹⁴, Fernando Perez-Ruiz ¹⁵, Philip Riches ¹⁶, Pascal Richette ¹⁷, Edward Roddy ¹⁸, Blanka Stiburkova ¹⁹, Alex So ²⁰, Lisa Stamp ²¹, Anne-Kathrin Tausche ²², Rosa Torres-Jimenez ²³ and Till Uhlig ²⁴, ¹University of Otago, Birmingham, ²University of Otago, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Nottingham, Nottingham, United Kingdom, ⁵Hospital General Universitario de Alicante, Alicante, Spain, ⁶University of Auckland, Auckland, New Zealand, ⁷Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁸Rijnstate Hospital, Arnhem, Netherlands, ⁹Viecuri MC, Venlo, Netherlands, ¹⁰Department of Internal Medicine and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands, ¹¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ¹²Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France, ¹³National Defense Medical College, Tokorozawa, Japan, ¹⁴University College Dublin, Dublin, Ireland, ¹⁵Hospital de Cruces, Vizcaya, Spain, ¹⁶The University of Edinburgh, Edinburgh, United Kingdom, ¹⁷Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ¹⁸Research Institute for Primary Care and Health Sciences and Keele Clinical Trials Unit, Keele, United Kingdom, ¹⁹Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic, ²⁰Universite de Lausanne, Lausanne, Switzerland, ²¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²²Universitatsklinikum Dresden, Dresden, Germany, ²³Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Spain, ²⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway
Background/Purpose: This study aimed to determine whether a polygenic risk score (PRS) based on gout-associated genetic variants is associated with gout disease severity phenotypes such…
Abstract Number: 2889 • 2019 ACR/ARP Annual Meeting
From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Natalie McCormick¹, Zachary Wallace ², Chio Yokose ³, April Jorge ³, Chana Sacks ⁴, John Hsu ⁵ and Hyon K. Choi ³, ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Department of General Internal Medicine, Massachusetts General Hospital; Department of Medicine, Harvard Medical School, Boston, MA, ⁵Mongan Institute, Massachusetts General Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA
Background/Purpose: Gout affects >4 million US adults aged ≥ 65 years, but little is known about the scale and drivers of public spending on gout…
Abstract Number: 2892 • 2019 ACR/ARP Annual Meeting
Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
Celine van de Laar¹, Martijn A.H. Oude Voshaar ², Carly Janssen ³, Matthijs Janssen ⁴, Maiwenn Al ⁵ and Mart A.F.J. van de Laar ⁶, ¹Transparency in Healthcare B.V., Hengelo, Overijssel, Netherlands, ²Transparency in Healthcare B.V. and Department of Psychology, Health & Technology, University of Twente, Hengelo, Netherlands, ³Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ⁴Department of Rheumatology, VieCuri Medical Center, Venlo, Netherlands, ⁵Erasmus University Rotterdam, Rotterdam, Netherlands, ⁶Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from…
Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Neus Quilis¹, Laura Ranieri², Jose Sanchez-Paya² and Mariano Andrés², ¹Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…
Abstract Number: 184 • 2018 ACR/ARHP Annual Meeting
Development of Focused Musculoskeletal Ultrasound Training for Primary Care Providers to Facilitate the Diagnosis of Gout: Initial Steps in an Educational Needs Assessment
Gary A. Kunkel¹, Andrea Barker², Jeremy Timm^3,4, Curry L. Koening⁵ and Michael J. Battistone⁶, ¹Division of Rheumatology, George Wahlen VA Medical Center/University of Utah, Salt Lake City, UT, ²Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ³Salt Lake City VA Medical Center, Salt Lake City, UT, ⁴Internal Medicine, University of Utah, Salt Lake City, UT, ⁵Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Gout is common in primary care settings, though establishing or excluding the diagnosis with confidence can be challenging, particularly if arthrocentesis is not feasible…
Abstract Number: 194 • 2018 ACR/ARHP Annual Meeting
A Survey on Gout-Related Knowledge Among Internal Medicine Residents
Sreelakshmi Panginikkod¹, Ahmad Raja², Ehsan Rajabirostami¹, Roshanak Habibi¹, Rasiya Hashim³, Sumia Matin Afridi⁴, Alvaro Altamirano Ufion⁵ and Venu Pararath Gopalakrishnan¹, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Presence Saint Francis Hospital, Evanston, IL, ³Presence Saint Joseph Hospital, Evanston, IL, ⁴Florida Hospital Orlando, Orlando, FL, ⁵Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: The prevalence of gout has risen in recent decades despite advancements in therapeutic options due to several reasons, including lack of adherence to treatment…
Abstract Number: 197 • 2018 ACR/ARHP Annual Meeting
Improving Clinical Decisions for Gout Management: Effect of Online Case-Based Education
Nimish Mehta, Piyali Chatterjee-Shin and Karen Badal, Medscape, LLC, New York, NY
Background/Purpose: Gout is a chronic condition with a considerable effect on patient health and quality of life. Despite the availability of multiple pharmacologic treatments and…
Abstract Number: 268 • 2018 ACR/ARHP Annual Meeting
The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand)
Nicola Dalbeth¹, Meihana Douglas¹, Kate MacKrill¹, Leanne Te Karu², Maria Kleinstäuber¹ and Keith Petrie¹, ¹University of Auckland, Auckland, New Zealand, ²Ngā Kaitiaki o Te Puna Rongoā o Aotearoa, Taupō, New Zealand
Background/Purpose: Recent research has suggested that renaming gout to a pathophysiological illness label (urate crystal arthritis) avoids inaccurate lay perceptions of gout and promotes…
Abstract Number: 410 • 2018 ACR/ARHP Annual Meeting
Experience of Finding Footwear and Factors Contributing to Footwear Choice in People with Gout
Angela Brenton-Rule¹, Nicola Dalbeth², Larry Edwards³ and Keith Rome⁴, ¹Podiatry, AUT University, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Florida at Gainsville, Gainsville, FL, ⁴School of Clinical Science, Health & Rehabilitation Research Institute, AUT University, Auckland, New Zealand
Background/Purpose: Gout frequently affects the foot, particularly the first metatarsophalangeal joint and Achilles tendon. People with gout commonly wear ill-fitting footwear that lacks cushioning and…
Abstract Number: 860 • 2018 ACR/ARHP Annual Meeting
Efficacy of a Web-Based Module to Educate Internal Medicine Housestaff on Gout
Allan C. Gelber¹, Olive Tang¹, Uzma Haque², Amanda Bertram³ and Stephen Sisson³, ¹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins School of Medicine, Lutherville, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Gout is a leading form of inflammatory arthritis. There is a paucity of data that examines the efficacy of teaching internal medicine (IM) residency…
Abstract Number: 866 • 2018 ACR/ARHP Annual Meeting
Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy
Chio Yokose¹, Yuqing Zhang², Nicola Dalbeth³, Jie Wei¹, Savvas Nicolaou⁴, Scott Baumgartner⁵, Jia Hu⁶, Maple Fung⁵ and Hyon K. Choi¹, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³University of Auckland, Auckland, New Zealand, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada, ⁵Formerly Ardea Biosciences, San Diego, CA, ⁶Heron Therapeutics, San Diego, CA
Background/Purpose: Gout is typically characterized as an acute monoarthritis involving the joints of the foot. However, polyarticular involvement develops, especially in advanced disease. Patterns of…

Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study

A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout

Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank

The First Phase 2a Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout

Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts

From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications

Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients

New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis

Development of Focused Musculoskeletal Ultrasound Training for Primary Care Providers to Facilitate the Diagnosis of Gout: Initial Steps in an Educational Needs Assessment

A Survey on Gout-Related Knowledge Among Internal Medicine Residents

Improving Clinical Decisions for Gout Management: Effect of Online Case-Based Education

The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand)

Experience of Finding Footwear and Factors Contributing to Footwear Choice in People with Gout

Efficacy of a Web-Based Module to Educate Internal Medicine Housestaff on Gout

Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy

Simple Search Results